NASDAQ · XERS
Healthcare · Biotechnology
$8.70
Up+$0.10 (+1.16%)
Updated Aug 22, 2026, 12:51 PM
SID Score
6.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
XERS closed at $8.70 after 21 trading sessions, up 4.57% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $8.61 | $8.81 | $8.535 | $8.70 | 1.56M |
| Aug 20, 2026 | $8.91 | $8.985 | $8.56 | $8.60 | 2M |
| Aug 19, 2026 | $8.93 | $9.02 | $8.77 | $8.78 | 2.25M |
| Aug 18, 2026 | $8.58 | $8.88 | $8.47 | $8.85 | 2.14M |
| Aug 17, 2026 | $8.45 | $8.545 | $8.2589 | $8.52 | 1.33M |
| Aug 14, 2026 | $8.33 | $8.67 | $8.25 | $8.60 | 1.37M |
| Aug 13, 2026 | $8.59 | $8.70 | $8.30 | $8.33 | 1.85M |
| Aug 12, 2026 | $8.365 | $8.52 | $8.235 | $8.49 | 1.73M |
| Aug 11, 2026 | $8.00 | $8.436 | $7.96 | $8.39 | 1.78M |
| Aug 10, 2026 | $7.96 | $8.07 | $7.80 | $7.99 | 1.62M |
| Aug 7, 2026 | $7.43 | $8.02 | $7.43 | $7.93 | 2.25M |
| Aug 6, 2026 | $7.19 | $7.435 | $7.05 | $7.36 | 3.72M |
| Aug 5, 2026 | $8.21 | $8.37 | $8.055 | $8.11 | 1.75M |
| Aug 4, 2026 | $8.13 | $8.28 | $8.04 | $8.19 | 1.84M |
| Aug 3, 2026 | $8.135 | $8.171 | $7.865 | $8.13 | 1.95M |
| Jul 31, 2026 | $8.34 | $8.405 | $7.99 | $8.08 | 1.62M |
| Jul 30, 2026 | $8.38 | $8.455 | $8.32 | $8.42 | 920.97K |
| Jul 29, 2026 | $8.23 | $8.485 | $8.23 | $8.38 | 1.19M |
| Jul 28, 2026 | $8.28 | $8.33 | $8.125 | $8.24 | 811.64K |
| Jul 27, 2026 | $8.40 | $8.465 | $8.20 | $8.21 | 873.43K |
| Jul 24, 2026 | $8.42 | $8.54 | $8.29 | $8.32 | 1.18M |
The latest Smart Investors Daily articles mentioning XERS.
XERS research
Company profile and research snapshot.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Barclays | Overweight | — |
| Mar 2, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 9, 2025 | Barclays | Overweight | — |
| Oct 29, 2025 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDTCompany ParticipantsAllison Wey - Senior Vice President of Investor...
Benzinga · Aug 6, 2026
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.00 by Infinity percent. This is a 1700 percent decrease over losses of $(0.01) per
Benzinga · Aug 6, 2026
Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $380.000 million-$390.000 million to $385.000 million-$390.000 million vs $385.229 million estimate.
Benzinga · Jun 11, 2026
Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XERS.
